ATE404556T1 - Substituierte hydantoine - Google Patents

Substituierte hydantoine

Info

Publication number
ATE404556T1
ATE404556T1 AT05771890T AT05771890T ATE404556T1 AT E404556 T1 ATE404556 T1 AT E404556T1 AT 05771890 T AT05771890 T AT 05771890T AT 05771890 T AT05771890 T AT 05771890T AT E404556 T1 ATE404556 T1 AT E404556T1
Authority
AT
Austria
Prior art keywords
substituted hydantoins
hydantoins
substituted
Prior art date
Application number
AT05771890T
Other languages
English (en)
Inventor
Xin-Jie Chu
Nader Fotouhi
Nicholas Huby
Norman Kong
Lee Mcdermott
John Moliterni
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE404556T1 publication Critical patent/ATE404556T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT05771890T 2004-08-17 2005-08-09 Substituierte hydantoine ATE404556T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US68299705P 2005-05-20 2005-05-20

Publications (1)

Publication Number Publication Date
ATE404556T1 true ATE404556T1 (de) 2008-08-15

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771890T ATE404556T1 (de) 2004-08-17 2005-08-09 Substituierte hydantoine

Country Status (16)

Country Link
US (1) US7427635B2 (de)
EP (1) EP1781649B1 (de)
JP (1) JP4927733B2 (de)
KR (2) KR20090006885A (de)
AR (1) AR050297A1 (de)
AT (1) ATE404556T1 (de)
AU (1) AU2005274390B2 (de)
BR (1) BRPI0514515A (de)
CA (1) CA2576599A1 (de)
DE (1) DE602005008986D1 (de)
ES (1) ES2313389T3 (de)
MX (1) MX2007001846A (de)
PL (1) PL1781649T3 (de)
RU (1) RU2383542C2 (de)
TW (1) TW200621764A (de)
WO (1) WO2006018188A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US7557221B2 (en) 2007-08-16 2009-07-07 Hoffman-La Roche Inc. Substituted hydantoins
JP2011506533A (ja) * 2007-12-20 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー Ｍｅｋキナーゼ阻害剤としての置換ヒダントイン
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
LT2303021T (lt) 2008-06-16 2019-06-25 University Of Tennessee Research Foundation Junginiai, skirti vėžio gydymui
WO2011000945A2 (en) * 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
EP2545187B1 (de) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Verfahren zur diagnose und behandlung von krebs bei patienten mit resistenz bzw. entwicklung einer resistenz gegenüber einer ersten krebstherapie
WO2011134969A1 (de) 2010-04-28 2011-11-03 Bayer Cropscience Ag Ketoheteroarylpiperidin und -piperazin derivate als fungizide
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN112739695B (zh) 2018-09-17 2025-03-18 永进药品工业株式会社 新型噻唑衍生物及其药学上可接受的盐
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
JP2023517106A (ja) * 2020-03-13 2023-04-21 ユンジン ファーム．カンパニー、リミテッド チアゾール誘導体またはその薬学的に許容される塩を含む癌の予防または治療用薬学組成物
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
MXPA02010746A (es) * 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de la glucocinasa que contienen hidantoina.
CN1286835C (zh) * 2001-07-19 2006-11-29 法玛西雅意大利公司 苯乙酰氨基噻唑衍生物、它们的制备方法和它们作为抗肿瘤剂的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors

Also Published As

Publication number Publication date
EP1781649B1 (de) 2008-08-13
US7427635B2 (en) 2008-09-23
DE602005008986D1 (de) 2008-09-25
EP1781649A2 (de) 2007-05-09
CA2576599A1 (en) 2006-02-23
WO2006018188A2 (en) 2006-02-23
PL1781649T3 (pl) 2009-01-30
TW200621764A (en) 2006-07-01
AU2005274390A1 (en) 2006-02-23
KR20070034635A (ko) 2007-03-28
RU2007109651A (ru) 2008-09-27
AU2005274390B2 (en) 2012-01-19
KR20090006885A (ko) 2009-01-15
WO2006018188A3 (en) 2006-05-18
JP2008509950A (ja) 2008-04-03
MX2007001846A (es) 2007-03-28
RU2383542C2 (ru) 2010-03-10
US20060041146A1 (en) 2006-02-23
BRPI0514515A (pt) 2008-06-10
KR100889721B1 (ko) 2009-03-23
ES2313389T3 (es) 2009-03-01
JP4927733B2 (ja) 2012-05-09
AR050297A1 (es) 2006-10-11

Similar Documents

Publication Publication Date Title
EP1744677A4 (de) Staumanschette
ATE414693T1 (de) Neuartige cis-imidazoline
ATE404556T1 (de) Substituierte hydantoine
EP1790757A4 (de) Suszeptor
DE602005012636D1 (de) Erung
ATE440097T1 (de) Substituierte hydantoine zur krebsbehandlung
DK1828514T3 (da) Hængsel
DE502005005196D1 (de) Direktional verfestigte bauteile
NO20070299L (no) Novel heterocyclic compounds
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
EP1801310A4 (de) Auskleidungsstruktur
DK1630309T3 (da) Afløb
DE502005004534D1 (de) Kämmmaschine
DE502006005182D1 (de) Heterocyclylamid-substituierte imidazole
DE602005004472D1 (de) Ausgleichsanordnung
DE112005002826A5 (de) Ausgleichseinheit
ATA2632004A (de) Ballenauflöser
SE0400785L (sv) Kompenseringsanordning
AT500198B1 (de) Ladewagen
DK1577449T3 (da) Afløbstilslutning
AT500249A3 (de) Scheibenegge
ATA10692004A (de) Scharnier
DE102005063244A8 (de) Modifiziertes 2-Nitroimidazol-Derivat
NO20044198L (no) Mikrofon
DE502005002684D1 (de) Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1781649

Country of ref document: EP